The FDA/DIA Forum provides a venue to discuss important statistical issues associated with the development and review of therapeutic drugs and biologics. The meeting is intended to be an annual, open dialogue to discuss FDA's issues, initiatives and guidance - emphasizing the statistical and regulatory challenges.
This conference is an opportunity for statisticians, clinicians and other interested professionals from industry, academia, CROs, and government agencies to learn about and assess current and emerging statistical methodologies and quantitative approaches used to develop evidence of the efficacy and safety of new drug and biologic therapeutic products.
This conference is an opportunity for statisticians, clinicians and other interested professionals from industry, academia, CROs, and government agencies to learn about and assess current and emerging statistical methodologies and quantitative approaches used to develop evidence of the efficacy and safety of new drug and biologic therapeutic products.
